welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

81% Informative

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. ( NASDAQ : NVAX ) stock, setting a price target of $ 10 .

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025 .

VR Score

81

Informative language

80

Neutral language

51

Article tone

formal

Language

English

Language complexity

55

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links